Authors
João Pedro Ferreira, Javed Butler, Stefan Anker, James Januzzi, Marina Panova-Noeva, Alexander Reese-Petersen, Naveed Sattar, Elke Schueler, Stuart Pocock, Gerasimos Filippatos, Milton Packer, Mikhail Sumin, Faiez Zannad
- Bibliographic Reference
- João Pedro Ferreira, Javed Butler, Stefan Anker, James Januzzi, Marina Panova-Noeva, et al.. Effects of empaglifozin on collagen biomarkers in patients with Heart Failure. Findings from the EMPEROR trials. European Journal of Heart Failure, 2023, ⟨10.1002/ejhf.3101⟩. ⟨hal-04324690⟩
- DOI
- https://doi.org/10.1002/ejhf.3101
- Department
- German Centre for Cardiovascular Research (DZHK) partner site Berlin
- Funding
- The EMPEROR-Reduced and Preserved trials were funded by Boehringer Ingelheim and Eli Lilly
- HAL Collection
- ['Publications du LORIA', 'Université de Lorraine', 'DCAC - Défaillance Cardiovasculaire Aiguë et Chronique', 'Pôle scientifique Biologie, Médecine, Santé']
- HAL Identifier
- 4324690
- Institution
- ['Centre Hospitalier Régional Universitaire de Nancy', 'Institut National de la Santé et de la Recherche Médicale', 'Université de Lorraine', 'Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy]', 'French-Clinical Research Infrastructure Network - F-CRIN [Paris]', 'Faculdade de Medicina da Universidade do Porto', 'Cardiovascular Research and Development Center (UnIC@RISE)', 'Baylor Scott & White Research Institute', 'University of Mississippi Medical Center', 'Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]', 'Berlin Institute of Health', 'Wrocław Medical University', 'Massachusetts General Hospital [Boston]', 'Harvard Medical School [Boston]', 'Boehringer Ingelheim Pharma GmbH & Co. KG', 'Nordic Bioscience A', 'S, CCBR', 'mainanalytics GmbH', 'London School of Hygiene and Tropical Medicine', '“Attikon” University Hospital', 'Baylor College of Medecine', 'Imperial College London', 'Boehringer Ingelheim International GmbH']
- Laboratory
- ['Défaillance Cardiovasculaire Aiguë et Chronique', "Centre d'investigation clinique plurithématique Pierre Drouin [Nancy]", 'Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy]', 'German Center for Cardiovascular Research', 'Nordic Bioscience A', 'S, CCBR', 'Baylor University Medical Center']
- Published in
- France
Table of Contents
- Submitted on 5 Dec 2023 1
- Effects of empaglifozin on collagen biomarkers in patients with Heart Failure. 2
- Findings from the EMPEROR trials 2
- DISCLOSURES 3
- Data sharing agreement 4
- Funding 5
- Abstract 6
- Background 6
- Aims 6
- Methods 6
- Results 6
- Conclusion 6
- Key-words 7
- Introduction 8
- Methods 8
- Study Population 8
- Supplementary Methods 1 2. 9
- Statistical Analyses 9
- Results 10
- Patients characteristics across collagen marker tertiles 10
- Table 1 11
- Supplementary Table 1A 11
- Supplementary Table 1B 11
- Supplementary Table 1C 11
- Supplementary Table 1D 11
- Supplementary Table 1E 12
- Outcome associations of collagen markers 12
- Supplementary Table 2A. 12
- Supplementary Tables 2B 2C 12
- Supplementary Table 2E. 12
- Table 2 13
- Supplementary Table 5 13
- Supplementary Table 4A-F 13
- Empagliflozin effect on collagen markers over time 13
- Table 3 Figure 1 13
- Table 4 and Supplementary Table 6 13
- Effect of empagliflozin on the study primary outcome across collagen marker 13
- Table 5 13
- Supplementary Table 3A 14
- Supplementary Table 3B 3D and 3E. 14
- Supplementary Table 3C 14
- Collagen biomarker correlations 14
- Supplementary Table 7A 14
- Supplementary Table 7B 14
- Supplementary Table 7C 14
- Discussion 14
- Limitations 17
- Conclusions 17
- References 18
- J Am Coll Cardiol 18
- Eur J Heart Fail 18
- J Am Coll Cardiol 18
- Nat Rev Cardiol 18
- J Am Soc Echocardiogr 18
- JACC Heart Fail 18
- Liver Int 18
- Eur J Heart Fail 18
- Int J Cardiol 18
- JACC Heart Fail 18
- Eur Heart J 19
- Heart 19
- Circulation 19
- Clin Res Cardiol 19
- Eur J Heart Fail 19
- Am J Cardiol 19
- PLoS One 19
- JACC Cardiovasc Imaging 19
- Heart 19
- Eur Heart J Cardiovasc Imaging 20
- J Am Coll Cardiol 20
- J Cell Mol Med 20
- Free Radic Biol Med 20
- Cardiovasc Diabetol 20
- Diabetologia 20
- Eur J Heart Fail 20
- N Engl J Med 20
- Eur Heart J 20
- Eur J Heart Fail 21
- Int Rev Connect Tissue Res 21
- Clin Biochem Rev 21
- Cardiovasc Pathol 21
- Circulation 21
- Liver Int 21
- Sci Rep 21
- Cardiovasc Res 21
- Cardiovasc Diabetol 21
- J Am Coll Cardiol 22
- Circulation 22
- Front Physiol 22
- Sci Rep 22
- Nephrol Dial Transplant 22
- Ann Clin Biochem 22
- J Gerontol A Biol Sci Med Sci 22
- Characteristics 23
- PICP tertiles 23
- Tertile 2 23
- Tertile 3 23
- Biomarker Tertile 1 25
- Tertile 2 25
- Tertile 3 25
- Standard Model Extended Model 25
- HR 95CI 25
- HR 95CI 25
- HR 95CI 25
- HR 95CI 25
- Biomarker Placebo 26
- Empagliflozin 26
- Week 12 26
- Week 52 26
- Subgroup Placebo Empagliflozin Week 12 Week 52 27
- Events Pbo 28
- Events empa. 28
- Empa. vs Pbo 28
- Intera ction trend 28